{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:28:16Z","timestamp":1763036896470},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.medcli.2014.12.021","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T22:03:31Z","timestamp":1424988211000},"page":"121-127","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["C\u00e1ncer de pr\u00f3stata"],"prefix":"10.1016","volume":"146","author":[{"given":"Joan","family":"Morote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Morales-B\u00e1rrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2014.12.021_bib0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.medcli.2014.12.021_bib0300","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.acuro.2012.06.006","article-title":"National prostate cancer registry 2010 in Spain","volume":"37","author":"C\u00f3zar","year":"2013","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.medcli.2014.12.021_bib0305","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7326\/0003-4819-155-11-201112060-00375","article-title":"Screening for prostate cancer: A review of the evidence for the U. S. Preventive Services Task Force","volume":"155","author":"Chou","year":"2011","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.medcli.2014.12.021_bib0310","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2012.08.066","article-title":"Outcome following active surveillance of men with screen-detected prostate cancer. Results from the G\u00f6teborg randomised population-based prostate cancer screening trial","volume":"63","author":"Godtman","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.juro.2014.01.030","article-title":"The roles of multiparametric MRI, PCA3, and PHI: Which is the best predictor of prostate cancer after a negative biopsy? Results of a prospective study","volume":"192","author":"Porpiglia","year":"2014","journal-title":"J Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0325","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/sj.bjc.6605815","article-title":"A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands","volume":"103","author":"Gupta","year":"2010","journal-title":"Br J Cancer."},{"key":"10.1016\/j.medcli.2014.12.021_bib0330","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.eururo.2013.03.025","article-title":"Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen","volume":"65","author":"Sonn","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0335","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrclinonc.2014.69","article-title":"Multiparametric MRI in prostate cancer management","volume":"11","author":"Johnson","year":"2014","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0340","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2014.12.021_bib0345","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11864-012-0221-5","article-title":"Active surveillance for prostate cancer: Overview and update","volume":"14","author":"Klotz","year":"2013","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0350","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1055-9965.EPI-09-1251","article-title":"Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening","volume":"19","author":"Savage","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.medcli.2014.12.021_bib0355","first-page":"359","article-title":"How accurate is our clinical Prediction of \u201cminimal prostate cancer\u201d?","volume":"15","author":"Leibovici","year":"2013","journal-title":"Isr Med Assoc J."},{"key":"10.1016\/j.medcli.2014.12.021_bib0360","first-page":"442","article-title":"Optimizaci\u00f3n del seguimiento del c\u00e1ncer de pr\u00f3stata en vigilancia activa","volume":"65","author":"Celma","year":"2014","journal-title":"Arch Esp Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0365","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: The PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0370","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol."},{"issue":"Spec No A","key":"10.1016\/j.medcli.2014.12.021_bib0375","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1102\/1470-7330.2011.9007","article-title":"Integrating multiparametric prostate MRI into clinical practice","volume":"11","author":"Padhani","year":"2011","journal-title":"Cancer Imaging."},{"key":"10.1016\/j.medcli.2014.12.021_bib0380","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.2011.10377.x","article-title":"The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance","volume":"109","author":"Van Poppel","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.medcli.2014.12.021_bib0385","first-page":"452","article-title":"Resultados de la vigilancia activa en c\u00e1ncer de pr\u00f3stata de riesgo bajo e intermedio","volume":"67","author":"Llorente","year":"2014","journal-title":"Arch Esp Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0390","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","article-title":"Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer","volume":"28","author":"Klotz","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0395","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0400","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.2010.09875.x","article-title":"Radical prostatectomy for cT3-4 disease: An evaluation of the pathological outcomes and patterns of care for adjuvant radiation in a national cohort","volume":"108","author":"Schreiber","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.medcli.2014.12.021_bib0405","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2013.05.033","article-title":"The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: A systematic review of the literature","volume":"66","author":"Gakis","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0410","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00345-013-1029-z","article-title":"Salvage radical prostatectomy as management of locally recurrent prostate cancer: Outcomes and complications","volume":"31","author":"Rosoff","year":"2013","journal-title":"World J Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0415","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: The essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0420","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1089\/end.2010.0295","article-title":"Retropubic, laparoscopic, and robot-assisted radical prostatectomy: A critical review of outcomes reported by high-volume centers","volume":"24","author":"Coelho","year":"2010","journal-title":"J Endourol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0425","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.eururo.2012.05.044","article-title":"Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy","volume":"62","author":"Novara","year":"2012","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2012.05.045","article-title":"Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy","volume":"62","author":"Ficarra","year":"2012","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0435","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2012.05.046","article-title":"Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy","volume":"62","author":"Ficarra","year":"2012","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0440","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2012.05.047","article-title":"Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy","volume":"62","author":"Novara","year":"2012","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0445","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.medcli.2014.12.021_bib0450","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.medcli.2014.12.021_bib0455","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0460","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase ii trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0465","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.juro.2012.10.061","article-title":"25-year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy","volume":"189","author":"Critz","year":"2013","journal-title":"J Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0470","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.12.021_bib0475","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2014.12.021_bib0480","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0485","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.01.005","article-title":"Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy","volume":"79","author":"Taira","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.medcli.2014.12.021_bib0490","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2011.09.055","article-title":"The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: A population-based analysis","volume":"83","author":"Shen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.medcli.2014.12.021_bib0495","first-page":"293","article-title":"Studies on prostate cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"10.1016\/j.medcli.2014.12.021_bib0500","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","article-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","volume":"178","author":"Morote","year":"2007","journal-title":"J Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0505","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials","volume":"355","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2014.12.021_bib0510","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): An open randomized phase iii trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2014.12.021_bib0515","first-page":"1046","volume":"77","author":"Nguyen","year":"2010","journal-title":"Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinicallt localized prostate cancer: a postrandomization analysis by risk group Int J Radiat Biol Phys"},{"key":"10.1016\/j.medcli.2014.12.021_bib0520","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0525","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2008.09.008","volume":"55","author":"Schr\u00f6der","year":"2009","journal-title":"Eur Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0530","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0535","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial","volume":"79","year":"1997","journal-title":"Br J Urol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0540","doi-asserted-by":"crossref","first-page":"727","DOI":"10.6004\/jnccn.2014.0074","article-title":"Intermittent versus continuous androgen deprivation therapy","volume":"12","author":"Higano","year":"2014","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.medcli.2014.12.021_bib0545","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2014.12.021_bib0550","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10555-013-9473-1","article-title":"Metastatic castration-resistant prostate cancer (CRPC): Preclinical and clinical evidence for the sequential use of novel therapeutics","volume":"33","author":"Mukherji","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.medcli.2014.12.021_bib0555","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.12.021_bib0560","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.12.021_bib0565","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.12.021_bib0570","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.12.021_bib0575","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2014.12.021_bib0580","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577531500041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577531500041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:46:18Z","timestamp":1691426778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002577531500041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S002577531500041X"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2014.12.021","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C\u00e1ncer de pr\u00f3stata","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2014.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}